title: Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
abstract: Although the V3 loop of the human immunodeficiency virus type 1 (HIV-1) envelope (Env) effectively elicits potent neutralizing antibody responses, the specificity of the antibody response is often restricted to T cell line adapted (TCLA) strains and a small subset of primary isolates, limiting its utility for an AIDS vaccine. In this study, we have compared Env immunogens with substituted V3 regions to combinations of strains from different clades and evaluated their ability to expand the breadth of the neutralizing antibody response. When the V3 region from HIV BaL was substituted for HIV HXB2, an effective neutralizing antibody response against several clade B primary isolates was elicited, but it remained restricted to neutralization of most clade B isolates. In an attempt to expand this response further, a linear epitope recognized by the broadly neutralizing 2F5 antibody was inserted into V3. A V3 2F5 epitope was identified that bound to 2F5 and elicited a potent 2F5 antibody response as an immunogen, but the antisera neutralized only a lab-adapted strain and not primary isolates. In contrast, combinations of Envs from clades A, B, and C, elicited neutralizing antibodies to a more diverse group of primary HIV-1 isolates. These studies suggest that combinations of Env immunogens, despite the limited reactivity of the V3 from each component, can be used to expand the breadth of the neutralizing antibody response.
authors.affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA.
authors.forename: Bimal K
authors.initials: BK
authors.lastname: Chakrabarti
authors.forename: Xu
authors.initials: X
authors.lastname: Ling
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Yang
authors.forename: David C
authors.initials: DC
authors.lastname: Montefiori
authors.forename: Amos
authors.initials: A
authors.lastname: Panet
authors.forename: Wing-Pui
authors.initials: WP
authors.lastname: Kong
authors.forename: Brent
authors.initials: B
authors.lastname: Welcher
authors.forename: Mark K
authors.initials: MK
authors.lastname: Louder
authors.forename: John R
authors.initials: JR
authors.lastname: Mascola
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Nabel
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology*; D015497:HIV-1 / Q000737:chemistry*; D006801:Humans; D007114:Immunization; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology; D014759:Viral Envelope Proteins / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D010446:Peptide Fragments; D014759:Viral Envelope Proteins